By Lisa Kerner
Charlotte, N.C., Oct. 19 - Xencor, Inc. raised $45 million in a private financing led by MedImmune Ventures, Inc. Other investors include Novo Nordisk, HealthCare Ventures and existing investor Zen Investments.
RBC Capital Markets was the exclusive placement agent for this transaction.
Proceeds will be used to advance the clinical development of two biologic drug compounds developed using Xencor's Protein Design Automation technologies.
The $45 million total includes the initial $6 million bridge financing announced in July and brings the company's total financing to date to $130 million, according to a company news release.
Xencor is a Monrovia, Calif., pharmaceutical company.
| Issuer: | Xencor, Inc.
|
| Issue: | Private financing
|
| Amount: | $45 million, including $6 million bridge financing
|
| Investors: | MedImmune Ventures, Inc. (lead), Novo Nordisk, HealthCare Ventures, Zen Investments
|
| Announcement date: | Oct. 19
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
